Lambda Variant (C.37) Spike Pseudotyping Vector
|pLV-SpikeV9||Unit size||Cat. code||Docs||Qty||Price|
Spike pseudotyping plasmid - Lambda Variant (C.37)
For lentiviral particle pseudotyping with the SARS-CoV-2 Spike (C.37 - Peruvian origin)
pLV-SpikeV9 has been specifically designed for the pseudotyping of lentiviral particles with the SARS-CoV-2 Spike (S) protein when co-transfected with plasmids encoding a reporter and accessory proteins (not provided). pLV-SpikeV9 encodes the full-length Spike sequence from the Lambda variant (C.37), and for optimal expression, it is codon-optimized and the C‑terminal ER-retention signal has been removed [1, 2].
InvivoGen also offers:
This plasmid encodes the Spike protein from the SARS-CoV-2 Lambda variant, first reported in Peru. This variant is classified as a member of Clade GR/452Q.V1/ C.37 lineage (Nextstrain/Pango lineage classification). It is characterized by the presence of mutations within the Spike coding region, of which, several are of concern [3,4].
- S1 domain: G75V, T76I, deletion (Δ)R246-G252, D253N, D614G
- RBD: L452Q, F490S
- S2 domain: T859N
General Plasmid Description
This plasmid features a potent mammalian expression cassette composed of the ubiquitous human-(h)CMV composite promoter, a rabbit β-globin intron directly upstream of the spike gene, and a rabbit β-globin polyadenylation (pAn) signal. The spike coding sequence includes the SARS-CoV-2 signal sequence and the S1/S2 furin cleavage site . These plasmids are selectable with ampicillin in E. coli.
- Generation of Spike pseudotyped lentiviral particles upon co-transfection with reporter and accessory protein plasmids (not provided).
- Screening of SARS-CoV-2 inhibitors including small molecules, monoclonal antibodies, or convalescent plasma.
1. Johnson, M.C. et al. 2020. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. J Virol 94.
2. Ou, X. et al. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11, 1620.
5. Coutard, B. et al. 2020. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 176, 104742.
- Origin: Lambda variant (C.37 lineage)
- Sequence Reference: EPI_ISL_3940379
- Codon Optimized
- ORF size: 3744 bp
- Forward rbt β-globin intron: TGGTTACAATGATATACACTG
- Reverse rbt β-globin pAn: CTCAAGGGGCTTCATGATGTC
- Plasmid construct is confirmed by restriction analysis and full‑length open reading frame (ORF) sequencing.
- After purification by ion-exchange chromatography, predominant supercoiled conformation is verified by electrophoresis.
pLV-SpikeV9 is provided as follows:
- 20 μg of lyophilized DNA
The product is shipped at room temperature.
Lyophilized DNA should be stored at -20 °C.
Resuspended DNA should be stored at -20 °C and is stable for up to 1 year.Back to the top
Spike-pseudotyping of lentiviral particles
InvivoGen's pLV-Spike plasmid collection has been designed for pseudotyping lentiviral particles with the SARS-CoV-2 Spike (S) protein. The S protein a structural glycoprotein expressed on the surface of SARS‑CoV-2. It mediates membrane fusion and viral entry into target cells upon binding to the host receptor ACE2 and its cleavage by cellular proteases such as TMPRSS2 . Notably, the C‑terminal cytoplasmic tail of the S protein encodes a presumptive endoplasmic reticulum (ER)‑retention motif (KxHxx), which has previously been shown to enable the accumulation of SARS‑CoV S proteins at the ER‑Golgi intermediate compartment (ERGIC) and facilitate their incorporation into new virions . The removal of this motif (d19) has been shown to increase the expression of the spike protein in pseudovirions [3,4].
Pseudotyped particle production involves the co-transfection of 293T cells with a reporter protein vector (e.g. GFP), one or several plasmids encoding the necessary lentiviral proteins, and the pseudotyping pLV-Spike plasmids. The transfected cells produce SARS‑CoV‑2 Spike (S)‑pseudotyped lentiviral particles, which can then be used to infect permissive cells, such as ACE2‑expressing HEK293-derived cells and ACE2‑TMPRSS2‑expressing A549-derived cells.
1. Hoffmann M. et al. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181:1-16.
2. Ujike, M. et al. 2016. The contribution of the cytoplasmic retrieval signal of severe acute respiratory syndrome coronavirus to intracellular accumulation of S proteins and incorporation of S protein into virus-like particles. J Gen Virol 97, 1853-1864.
3. Johnson, M.C. et al. 2020. Optimized pseudotyping conditions for the SARS-COV2 Spike glycoprotein. J Virol. 94(21):e01062-20
4. Ou, X. et al. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11, 1620.